阿霉素
MCF-7型
DNA
拓扑异构酶
DNA合成
DNA损伤
细胞培养
分子生物学
生物
化学
癌症研究
生物化学
化疗
癌细胞
人体乳房
遗传学
癌症
作者
Frank A. Fornari,Joyce K. Randolph,Jack C. Yalowich,M K Ritke,David A. Gewirtz
出处
期刊:Molecular Pharmacology
[American Society for Pharmacology and Experimental Therapeutics]
日期:1994-04-01
卷期号:45 (4): 649-656
被引量:426
标识
DOI:10.1016/s0026-895x(25)10149-1
摘要
The capacity of doxorubicin to inhibit topoisomerase II in the MCF-7 breast tumor cell line is supported by the induction of protein-associated single-strand breaks in DNA, as well as by interference with the decatenation activity of nuclear extracts. Doxorubicin also produces non-protein-associated DNA strand breaks (at a supraclinical concentration of 5 microM), which may indicate damage mediated via the generation of free radicals. However, no strand breaks are detected in DNA of MCF-7 cells at the IC50 for doxorubicin (approximately 0.1 microM). At doxorubicin concentrations of 0.05, 0.1, and 0.5 microM, at which growth is inhibited by approximately 15, 50, and 75%, respectively, doxorubicin interferes with radiation-induced unwinding of DNA; doxorubicin also produces a concentration-dependent inhibition of DNA synthesis that corresponds closely to growth inhibition. These studies suggest that DNA strand breaks fail to fully account for the antiproliferative activity of doxorubicin in the MCF-7 breast tumor cell line. Compromised DNA synthesis associated with interference with DNA unwinding may contribute to growth inhibition in MCF-7 cells exposed to doxorubicin.
科研通智能强力驱动
Strongly Powered by AbleSci AI